134 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 30. derivative financial instruments Continued interest rate swaps the Group uses interest rate swaps to manage its exposure to interest rate movements on its bank borrowings.
these contracts have nominal values of usD 173,164,000 2010: usD 45,404,000 and have fixed interest payments at rates ranging from 1.41% to 4.34% 2010: 1.91% to 4.75% for periods up until 2018 and have floating interest receipts at liBOr or euriBOr.
the fair value of swaps entered into by the Group is estimated as a liability of usD 1,699,000 2010: liability of usD 1,287,000. theseamounts are based on market values provided by the banks that originated the swaps and are based on equivalent instruments at the balance sheet date.
some of these interest rate swaps are designated as effective cash flow hedges and the movement in fair value totalling a lossof usD422,000 2010: usD loss of 339,000 has been reflected in equity.
the remaining outstanding interest rate swaps that the Group was committed to at the year end are held at fair value through profit and loss.
the movement in fair value in the year resulted in a gain of usD10,000 which has been recognised in the statement of comprehensive income for the year ended 31 December 2011 2010: loss of 16,000 in respect of such derivatives.
the Group believes that the effect on the value of interest rate swaps by interest rate fluctuations will not materially affect the financial position of the Group.
31. share capital 2011 2010 number 000 $000 number 000 $000 Issued and fully paid included in shareholders equity: At 1 January 193,517 34,525 191,628 34,236 issued during the year 2,334 379 1,889 289 At 31 December 195,851 34,904 193,517 34,525 32. non-controlling interests 2011 2010 $000 $000 At 1 January 6,378 7,372 share of profit 3,362 678 dividends paid 100 issue of equity shares of subsidiaries 488 currency translation gain loss 195 1,701 acquisition of subsidiaries 26,650 29 adjustment arising from change in non-controlling interests 14,914 At 31 December 22,059 6,378 33. own shares Own shares represent 571,000 2010: 562,000 Ordinary shares in the company held by sanne trust company limited an independent trustee.
During the year the company issued 700,000 Ordinary shares to the independent trustee to meet short-term commitments in relation to employee share plans.
691,000 shares were utilised during the year.
the market value for the own shares at 31 December 2011 was usD 5,472,000 2010: 7,056,000. in 2011, no shares were acquired.
thebook value of the retained own shares at 31 December 2011 is usD 2,222,000 2010: usD 2,220,000. the trustee holds these shares tomeet long-term commitments in relation to employee share plans.
